Ovarian Cyst

This trial investigates different surgical methods for treating endometriomas, which are ovarian cysts larger than 2 cm, in adult women aged 18 to 43 who have symptoms like pelvic pain or fertility issues. The study aims to compare pregnancy rates within 24 months after surgery, along with birth rates, types of pregnancies, recurrence of cysts, complications, and changes in pain levels. Researchers seek to find which surgical approach yields better pregnancy outcomes and fewer problems. Participants are randomly assigned to one of three surgical treatments cystectomy, where the cyst wall is gently removed from the ovary plasma vaporization, which destroys the cyst wall using plasma energy or ethanol sclerotherapy, which uses alcohol to destroy the cyst lining. After surgery, women will have follow-up visits at 3 months and 24 months to monitor their recovery and pregnancy progress. During the study, participants will be evaluated through medical imaging, symptom questionnaires, and monitoring of pregnancy outcomes including natural and assisted pregnancies. Researchers will track recurrence of cysts over 24 months and assess pain using a standardized scale. Safety and complications will be recorded during the first 3 months post-surgery. The total participation spans from surgery through two years of follow-up evaluations.

Researchers are evaluating the combination of adebrelimab and fuzuloparib in people with recurrent platinum-resistant ovarian cancer who have not received previous systemic antitumor therapy for this cancer. This exploratory, single-arm Phase 2 study focuses on assessing the effectiveness and safety of this drug combination in women with this condition. The study is led by Fujian Cancer Hospital and aims to measure outcomes over a 3-year period. Participants receive adebrelimab at 20 mgkg intravenously every three weeks and take fuzuloparib orally at 100 mg twice daily. The study does not include a comparator group and follows a single treatment approach. Treatment continues under medical supervision while researchers monitor the participants response and safety. During the study, participants undergo regular evaluations including scans to measure tumor response using RECIST1.1 criteria, blood tests, and physical assessments. Researchers track the primary outcome of objective response rate over three years, along with secondary outcomes like overall survival, progression-free survival, and disease control rate. Safety monitoring and adherence to study procedures are maintained throughout the study, with participation lasting up to three years.

Pancreatic ductal adenocarcinoma PDAC is a serious cancer with low 5-year survival rates, mainly due to late-stage diagnosis. Researchers are studying an AI-powered screening system that uses non-contrast computed tomography NCCT scans taken during routine medical visits or health check-ups. This observational, multi-center study aims to improve early detection of PDAC and its precursor lesions, potentially leading to better patient outcomes and wider access, especially in underserved areas. The study will use a deep learning AI model to automatically detect abnormalities in the pancreas from NCCT images. Cases flagged by the AI will be reviewed by two independent radiologists. If the radiologists suspect cancer or precursor lesions, participants will undergo further testing such as blood tests and advanced imaging. Those diagnosed with PDAC or precursor lesions will receive specialized treatment and consultation, while those without a diagnosis will be followed clinically for at least one year. Participants will be involved through routine CT scans without additional imaging initially. The study will measure the AI systems accuracy by tracking detection rates, recall rates for further testing, and positive predictive value over three years. Secondary outcomes include the proportion of early-stage PDAC detected and survival time over five years. The study involves multiple hospitals and technical support, with ongoing monitoring and clinical follow-up for confirmed or negative cases.

Pancreatic ductal adenocarcinoma PDAC is a highly aggressive cancer with a low 5-year survival rate, making early diagnosis vital to improving outcomes. Current screening methods are limited and often miss early-stage disease, especially for the general public. Researchers are evaluating the use of an Artificial Intelligence AI system called PANDA combined with low-dose computed tomography LDCT to enhance pancreatic cancer screening in a prospective, multicenter, observational cohort, aiming to improve early detection and reduce unnecessary procedures. Participants will undergo annual LDCT scans analyzed by the PANDA AI system. Abnormal findings identified by the AI are reviewed by a multidisciplinary team MDT to decide next steps suspected pancreatic cancer or precursor lesions lead to hospital examinations benign lesions receive personalized monitoring and cases confirmed as normal by MDT will have at least one year of follow-up. If abnormalities appear during follow-up, participants will be managed accordingly. This approach focuses on evaluating detection rates, predictive values, consensus, and recall rates over two years. During the study, participants will complete LDCT exams and consent to follow-up assessments based on AI and MDT findings. Researchers will monitor pancreatic cancer detection rates, early-stage cancer proportions, and safety indicators like false positives and unnecessary invasive procedures. Follow-up will continue for at least one year for some participants, with ongoing monitoring to assess the effectiveness and safety of AI-assisted LDCT screening in a health check-up population.

Researchers are evaluating the impact of Transvaginal Natural Orifice Transluminal Endoscopic Surgery vNOTES compared to conventional abdominal laparoscopy CAL for benign adnexal surgery in women aged 18 to 70. The study aims to confirm that vNOTES does not negatively affect womens sexual function after surgery, addressing concerns about vaginal scarring and its effects on sexual activity. Secondary goals include assessing vNOTES efficiency, complications, and the quality of histological analysis of surgical specimens. Participants will be randomly assigned to receive either the vNOTES or CAL surgical technique for procedures such as cystectomy, oophorectomy, salpingectomy, or tubal sterilization. Both approaches involve minimally invasive surgery, with vNOTES using the vaginal route and CAL using abdominal laparoscopy. The study also examines pain, hospital stay length, patient satisfaction, and surgical complications during and up to 30 days after surgery. Women in the study will complete questionnaires before surgery and at 3 and 6 months afterward to assess sexual function, couple satisfaction, and pain during sex. Medical and general data will be collected at enrollment, during hospitalization, and one month post-surgery. The main outcomes measured include quality of sexual life and postoperative recovery, while monitoring safety and the effectiveness of both surgical methods throughout the study period.

This research aims to compare the effects of using electrosurgical energy versus hemostatic sealants to control bleeding during laparoscopic cystectomy for ovarian cysts in women of childbearing age. Ovarian cysts are common, and while many resolve without treatment, some pathologic cysts require surgery. Laparoscopic ovarian cystectomy is a preferred minimally invasive surgery that preserves ovarian function and future fertility, but controlling bleeding from the remaining ovarian tissue is a key challenge. The study involves two groups one where electrosurgical energy is used to stop bleeding, and another where a hemostatic sealant is applied directly to the bleeding tissue. Electrosurgical energy methods include bipolar electrosurgery that minimizes thermal damage, while the hemostatic sealant such as Surgicel helps form clots to stop bleeding. Both treatment techniques are applied during laparoscopic removal of ovarian cysts. The study is randomized and single-blind. Participants will undergo laparoscopic surgery with assigned hemostasis methods. Researchers will measure the hemostasis time on the first day after surgery. The study will also monitor ovarian reserve and other outcomes through clinical assessments. Participation lasts from surgery through the primary outcome assessment, with safety and effectiveness closely observed. The trial is sponsored by Kafrelsheikh University and will run until May 2026.

This research aims to compare two methods for controlling bleeding during laparoscopic ovarian cystectomy in women with ovarian endometriosis. The study evaluates how well a hemostatic agent versus suturing preserves ovarian function, controls bleeding, and ensures safety during surgery. It focuses on women aged 19 to 45 who are scheduled for this procedure to address benign ovarian cysts caused by endometrioma. Participants will be randomly assigned to one of two groups. In the first group, bleeding is controlled using a hemostatic agent called EVICEL4 Fibrin Sealant, which contains thrombin and coagulating proteins. If bleeding continues, additional methods like electrocoagulation and suturing may be used. The second group uses barbed sutures on the ovarian tissue to stop bleeding, with electrocoagulation as a backup if needed. This approach allows comparison of the hemostatic effectiveness and impact on ovarian tissue. During the study, ovarian function will be assessed before surgery and at 12 and 48 weeks after surgery by measuring Anti-Mullerian Hormone AMH levels and ovarian volume. Researchers will also track blood loss, hemoglobin levels, time to achieve hemostasis, adverse events, and hospital stay length. Participants will be monitored closely to evaluate safety and the preservation of ovarian function over nearly one year after surgery.

Researchers are evaluating two surgical techniques for treating endometriomas to determine which better preserves ovarian reserve. The study focuses on women with endometriotic cysts who experience infertility or pain. The trial compares the combined technique and CO2 laser vaporization only, assessing ovarian reserve through Anti-Mllerian Hormone AMH serum levels before and after surgery. Two surgical methods are studied the combined technique involves stripping about 80% of the cyst wall followed by ablation of the remaining 20%, while the CO2 laser vaporization method uses CO2 laser to ablate the entire inner cyst wall after draining and inspecting the cyst. The laser settings are carefully controlled to preserve healthy tissue beneath the cyst surface. Participants will have their AMH levels measured three months after surgery to assess ovarian reserve. The study includes women aged 18 to 40 with specific cyst sizes and requires contraception use before surgery. Researchers monitor outcomes through hormone measurements and clinical follow-up to evaluate the effect of each surgical approach on ovarian function.

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This study compares sclerotherapy to expectant management to determine which approach better helps manage symptoms and quality of life impacts associated with this common form of endometriosis. Participants are randomly assigned to either receive ultrasound-guided alcohol sclerotherapy involving puncture and alcohol treatment of the cysts or to be managed expectantly with standard pain management if needed. The sclerotherapy procedure involves a 15-minute application of absolute ethanol followed by a wash. Both groups will be followed for six months, with assessments at baseline and 6 months post-treatment. During the study, participants will complete quality of life and pain assessments using standardized tools, provide blood and urine samples for biomarker analysis, and undergo ovarian reserve evaluations. Researchers will monitor adverse events, cyst recurrence, fertility outcomes, and healthcare costs. Pregnancy outcomes will be followed for an average of two years. The main outcome is quality of life measured at baseline and 6 months.

This research investigates the use of ultrasonography US-guided ethanol sclerotherapy for treating ovarian endometriomas, which are cystic masses caused by endometrial tissue collecting fluid. These cysts can cause pelvic pain, painful menstruation, irregular uterine bleeding, and infertility. Endometriomas are commonly treated with medication or surgery, but this study explores a less invasive approach that may avoid damage to the ovary. The study involves women with endometriomas sized between 25 and 100 mm who will undergo US-guided aspiration of the cyst fluid followed by sclerotherapy using 95% ethanol. The ethanol is left inside the cyst for 10 to 15 minutes and then removed. This procedure is done under general anesthesia with antibiotic protection given beforehand. After the procedure, some participants may undergo in vitro fertilization IVF about a month later to assess fertility outcomes. Participants will be monitored to evaluate the effects of sclerotherapy on ovarian function and fertility treatment results over three years. Researchers will collect samples for cytology testing and track outcomes related to ovarian reserve and pregnancy rates. The study aims to measure how this treatment impacts ovarian health and IVF success while avoiding the ovarian damage sometimes caused by surgery.